FDA Approves Risperdal for Treatment of Irritability Associated with Autistic Disorder
The U.S. Food and Drug Administration (FDA) has approved the use of Risperdal for the treatment of irritability associated with autistic disorder. This is the first time the FDA has approved a drug for the treatment of symptoms of autism in children and adolescents. The drug is marketed by Janssen, L.P, a subsidiary of Johnson & Johnson.
Click here for the company press release. Click here to read a news story from Reuters.
Click here for the company press release. Click here to read a news story from Reuters.
|
|
|
|
|
|
|
|
||||||
